Literature DB >> 10479174

Cross-reactive antibodies prevent the lethal effects of Staphylococcus aureus superantigens.

S Bavari1, R G Ulrich, R D LeClaire.   

Abstract

The exotoxins produced by Staphylococcus aureus, staphylococcal enterotoxins (SE) A-E and toxic shock syndrome toxin (TSST)-1, which are associated with serious diseases, including food poisoning and toxic shock syndrome, are termed superantigens (SAgs). To examine whether common antigenic epitopes were present and whether vaccination with 1 bacterial SAg could protect against challenge with a different SE or TSST-1, mice were vaccinated with SEA, SEB, SEC1, or TSST-1 individually or in combination. Mice injected with a single toxin developed high antibody titers against other SAgs. Marked improvement in survival was observed when immunized mice were challenged with a heterologous toxin. Mice vaccinated with a mixture of toxins were fully protected against 1 or multiple toxin challenges, indicating no interference effects of multivalent vaccinations. More importantly, higher titers were found against each SAg with the multivalent vaccination than with injection with a single SAg. Thus, immunizations with 1 SAg can induce cross-protective antibodies to heterologous SAgs, and multicomponent vaccination can enhance antibody responses against each bacterial SAg.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10479174     DOI: 10.1086/314977

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Gram-Positive Pneumonia.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

2.  A mutant of staphylococcal enterotoxin C devoid of bacterial superantigenic activity elicits a Th2 immune response for protection against Staphylococcus aureus infection.

Authors:  Dong-Liang Hu; Jing-Chun Cui; Katsuhiko Omoe; Hiroshi Sashinami; Yuichi Yokomizo; Kunihiro Shinagawa; Akio Nakane
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Human antibodies to bacterial superantigens and their ability to inhibit T-cell activation and lethality.

Authors:  R D LeClaire; S Bavari
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Structural basis for the neutralization and specificity of Staphylococcal enterotoxin B against its MHC Class II binding site.

Authors:  Tian Xia; Shuaiyi Liang; Huajing Wang; Shi Hu; Yuna Sun; Xiaojie Yu; Jun Han; Jun Li; Shangjing Guo; Jianxin Dai; Zhiyong Lou; Yajun Guo
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

Review 5.  Virulence Factor Targeting of the Bacterial Pathogen Staphylococcus aureus for Vaccine and Therapeutics.

Authors:  Trevor L Kane; Katelyn E Carothers; Shaun W Lee
Journal:  Curr Drug Targets       Date:  2018       Impact factor: 3.465

6.  Lack of muco-cutaneous signs of toxic shock syndrome when T cells are absent: S. aureus shock in immunodeficient adults with multiple myeloma.

Authors:  N S Kamel; M C Banks; A Dosik; D Ursea; A A Yarilina; D N Posnett
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

7.  Generation, characterization, and epitope mapping of neutralizing and protective monoclonal antibodies against staphylococcal enterotoxin B-induced lethal shock.

Authors:  Avanish K Varshney; Xiaobo Wang; Emily Cook; Kaushik Dutta; Matthew D Scharff; Michael J Goger; Bettina C Fries
Journal:  J Biol Chem       Date:  2011-01-13       Impact factor: 5.157

8.  Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination.

Authors:  Ross D LeClaire; Robert E Hunt; Sina Bavari
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

9.  Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B.

Authors:  Eileen A Larkin; Bradley G Stiles; Robert G Ulrich
Journal:  PLoS One       Date:  2010-10-11       Impact factor: 3.240

10.  Measurement of staphylococcal enterotoxin B in serum and culture supernatant with a capture enzyme-linked immunosorbent assay.

Authors:  E Cook; X Wang; N Robiou; B C Fries
Journal:  Clin Vaccine Immunol       Date:  2007-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.